Hiroshima, Nagasaki, Hanford, and Fukushima Critical Review on Radio Epidemiology Studies

2015/9/21

The Fifth Citizen-Scientist International Symposium on Radiation Protection, Tokyo

Yutaka Hamaoka hamaoka@fbc.keio.ac.jp Faculty of Business and Commerce,Keio University

Agenda

- Research Purpose
- Brief Introduction to LSS studies
- Limitations of LSS studies
- Re-analysis of LSS 14 data
 - Limiting samples to lower dose
 - Model selection
 - Effect of Aggregation
- Re-analysis of Nuclear worker data
- Possible warning for Fukushima?
- Summary and Conclusion

- Critically examine methodology of LSS reports that seems to be a standard approach in Radio-epidemiology
- Re-analyze LSS 14 data to confirm problems of their analysis.
- Re-analyze Nuclear worker data in US facilities with which previous studies failed to detect effect of radiation with individual level data
- Review studies on radiation and thyroid anomalies.
- Analyze relationship between exposure dose (UNSCEAR estimates) and thyroid nodules using Fukushima thyroid screening data.

Introduction to A-Bomb Survivor Data Analysis

- Since 1950, Radiation Effects Research Foundation (formerly Atomic Bomb Casualty Commission) has investigated effects of radiation on health with a cohort of a-bomb survivors that consists of some 94,000 directly exposed to the bombings and 27,000 who entered the city just after the bombings.
- Life Span Study (LSS)
 - Almost every five or ten years, the RERF has published reports that examine relationships between radiation exposure and cancer mortality, cancer incidents, non-cancer mortality, etc.
- This study critically examines the Report 13 (Preston et al. 2003) and the Report 14 (Ozasa et al. 2012), then reanalyze newest and publicly available LSS14 data.

Brief Introduction to LSS studies Summary of LSS14 Data (Ozasa et al. 2012)

Colon	Subjecte	Ci	ty	Se	ex	Age at		Mortality	
(Gy)	Subjects	Hiroshima	Nagasaki	Male	Female	posure	Total	Solid cancer	Leukemia
~0.005	38,509	56.3%	43.7%	41.4%	58.6%	22.3	22,270 (100%)	4,621 (20.7%)	99 (0.4%)
~0.1	29,961	75.9%	24.1%	41.2%	58.8%	22.1	17,292 (100%)	3,653 (21.1%)	78 (0.5%)
~0.2	5,974	84.3%	15.7%	39.9%	60.1%	23.2	3,557 (100%)	789 (22.2%)	18 (0.5%)
~0.5	6,356	79.7%	20.3%	39.0%	61.0%	23.4	3,898 (100%)	870 (22.3%)	27 (0.7%)
~1.0	3,424	69.3%	30.7%	41.3%	58.7%	23.1	2,061 (100%)	519 (25.2%)	30 (1.5%)
~2.0	1,763	65.3%	34.7%	46.1%	53.9%	22.2	1,1 27 (100%)	353 (31.3%)	39 (3.5%)
2.0+	624	69.7%	30.3%	48.6%	51.4%	20.1	415 (100%)	124 (29.9%)	27 (6.5%)
Total	86,611	67.5%	32.5%	41.2%	58.8%	22.4	50,620 (100%)	10,929 (21.6%)	318 (0.6%)

Relationships between Exposure and Mortality



Publicly Available Data

Individual-level data is Tabulated by

Dose	city	sex	gd3	ahs	agexca	agecat	ctime	doseca	subjec	pyr	agex	age	colon1	ste	death	solid	esoph	sto
2000	1	1	1	0	1	2	1	1	259	594.8	1.656	8.404	2.641	2.	0	0	0	
22 categories	1	1	1	0	1	2	1	2	726	1701	1.712	8.432	10.54	10	0	0	0	
	1	1	1	0	1	2	1	3	277	571.2	1.862	8.505	29.09	2!	1	0	0	
city	1	1	1	0	1	2	1	4	151	335.2	1.786	8.466	49.08	5(1	0	0	
ony	1	1	1	0	1	2	1	5	109	252.3	1.726	8.44	70.32	7:	0	0	0	
SOV	1	1	1	0	1	2	1	6	79	177.8	1.712	8.432	90.46	9;	0	0	0	
367	1	1	1	0	1	2	1	7	98	209.6	1.807	8.474	112.1	1	1	0	0	
Ago of oxposure	1	1	1	0	1	2	1	8	61	135.1	1.87	8.511	137.8	1	0	0	0	
Age al exposure	1	1	1	0	1	2	1	9	64	142	1.7	8.415	163.2	10	1	0	0	
Attained and	1	1	1	0	1	2	1	10	63	131	1.94	8.546	187.4	1!	0	0	0	
Attained age	1	1	1	0	1	2	1	11	63	161.8	1.506	8.329	222.3	2;	0	0	0	
_	1	1	1	0	1	2	1	12	60	118.4	2.026	8.56	271.9	21	2	0	0	
	1	1	1	0	1	2	1	13	118	258.2	1.777	8.459	393	4	1	0	0	
	1	1	1	0	1	2	1	14	59	144.9	1.659	8.405	592.8	6	1	0	0	
	1	1	1	0	1	2	1	15	4	8.594	2.052	8.602	811.3	8	0	0	0	
	1	1	1	0	1	2	1	16	3	3.782	3.063	9.108	1060	1	0	0	0	

These variables must be included in the analysis of effect of radiation on health.

RERF Downloadable Data Life Span Study Report 14. Cancer and noncancer disease mortality data, 1950–2003

http://www.rerf.or.jp/library/dl/index.html

Exposure and Solid Cancer Mortality 8 d:Exposure β_0 : Percentage of Solid cancer in Total Mortality 80 β_1 : Increase of Solid cancer mortality exposed 1 Gy. Percentages in All Cause of Death Size of circle proportionate with # of subjects. Linear Model 60 $\beta_0 + \beta_1 d$ β1 4 20 0 . . 1.0 1.5 2.0 2.5 0.0 0.5 Colon Dose(Gy)

8

Various Dose-Response Functions



Excessive Relative Risk Model

Mortality rate after exposure (d)

=Baseline or background mortality rate at zero dose

×[1+Characteristics of survivors × f(d)]

Excessive Relative Risk

f(d): Dose-response function

Characteristics of survivors

= $(1+\gamma_1Sex)\times exp{\gamma_2(Age at exposure-30)+\gamma_3log(Attained age/70)}$

- Assumptions of the Model
 - Exposure could raise mortality (Excessive Relative Risk)
 - Relationship between exposure and increase in mortality rate is given doseresponse model.
 - Dose-response is modified by survivors 'sex, age at exposure, and attained age.
 - Mortality at 70 years old of those who were exposed at 30 years old is used as reference for estimation.

Results of Estimation (Solid Cancer Mortality, Linear Model)

	Estimates	Std. Error	t- value	P-value		95% Confidence Interval	
Colon Dose (Gy)	0.42	0.05	8.40	<0.001	***	(0.32, 0.52)	
Age at Exposure	-0.35	0.08	-4.25	<0.001	***	(-0.51,-0.19)	
Attained age	-0.86	0.42	-2.03	0.04	**	(-1.69,-0.03)	
Sex(Male-1,Female=1)	0.34	0.09	3.92	<0.001	***	(0.17, 0.51)	
Ν			Ę	53782			
Deviance	18299.0						

Significance Level ***: 1% **:5% *:10%

Age at Exposure and ERR exp{ γ_2 (Age at exposure-30)+ γ_3 log(Attained age/70)}



Limitations in LSS Studies

- Through our critical review of the Life Span Survey (LSS) Report 13 (Preston et al., 2013) and Report 14 (Ozasa et al. 2012), the limitations were identified.
- They are summarized the next table (Hamaoka 2015b).

Focuses of our analysis.

- Limiting samples to lower dose ranges
- Incomplete model selection
- Aggregation of individual level data

Limitations in LSS13 and LSS14(Hamaoka 2015b)

			LSS 13	LSS 14
	Limitations		1950–1997	1950–2003
			(Preston et al. 2003)	(Ozasa et al. 2012)
Data Management	Aggregation of individual data	Loss of statistical power	\checkmark	\checkmark
Madal	Multicolinearlity in LQ	Unstable esitimates	\checkmark	\checkmark
Formulation	Does not estimate threshold itself	Statistical significance can not be tested.	\checkmark	\checkmark
	Limiting samples to lower dose range		\checkmark	
Model estimation	Additional analysis that compare L, Q, and LQ model limiting samples to less than 2Gy.	Loss of statistical power		\checkmark
	Pooled analysis with Hiroshima and Nagasaki	Neglecting differences	\checkmark	\checkmark
Model	All of estimates are not displayed, such as modification terms, that helps model diagnosis and model improvement.	Insufficient model diagnosis	\checkmark	\checkmark
	Incomplete model selection	Confusing results	\checkmark	\checkmark
	14			

Limiting Samples to Lower Dose (Preston et al. 2003)

- LSS Report 13 shows estimation using a linear model and restricting to the low dose range yields significant coefficients beyond the 0-125 mSv range.
- This is an inappropriate conclusion neglecting a decrease in the sample size that cause loss of statistical power.
- All data should be used so as not to lose statistical power.

Dose Range (Sv)	ERR/Sv	t-value	P-value	
0-0.05	0.93	1.09	0.150	
0-0.1	0.64	1.16	0.300	
0-0.125	0.74	1.95	0.025	**
0-0.15	0.56	1.75	0.045	**
0-0.2	0.76	2.62	0.003	***
0-0.5	0.44	3.67	< 0.001	***
0—1	0.47	4.70	< 0.001	***
0–2	0.54	7.71	< 0.001	***
0–4	0.47	9.40	<0.001	***

UNSCEAR Follows This Inappropriate Analysis

UNSCEAR2006 Report

They conducted the same analysis for cancer mortality and cancer incident with a model taking uncertainty in dose estimates into account. They found the lowest dose ranges that obtained significant coefficients of radiation were 0-200 mSv for solid cancer mortality, and 0-250 mSv for solid cancer incidents.

UNSCEAR 2011 Report (Summary of UNSCEAR 2006)

"Statistically significant elevations in risk are observed at doses of 100 to 200 mGy and above. UNSCEAR(2011, parag. 25)"

Incomplete Model Selection Results of LSS14 (L, Q, LQ, Dose category dummy)

- Model fit was compared among nested L,Q and LQ models with loglikelihood test. Then, L model was selected as the best model.
- However, fit of dosecategory dummy model is not discussed.
- Some researcher insists "hormesis effect", because dose-category dummy model has negative estimates at the lower dose range.



Results of LSS14 (Linear Spline Model)

- Inappropriate analysis: limiting samples to lower dose was not conducted in LSS Report 14, Linear spline model that allows a change in slopes at pre-determined boundary values was applied for the analysis.
- Linear spline (L1L2) $\beta_1 d$ (d<d₀) β_2 (d-d') (d≥d₀)
- The figure exhibit estimates and their 95% confidence interval. Ozasa et al. 2012 explains that "The lowest dose range with a significant ERR for all solid cancer was 0 to 0.20 Gy with an estimated ERR/Gy of 0.56"
 - based on this results threshold at 0.Gy is insisted by a researcher.



FIG. 5. Excess relative risk per Gy (ERR/Gy) for all solid cancer for selected dose ranges. The figure shows the ERR/Gy and 95% CI for a dose range from zero to a given dose based on the linear model for the full data that allowed for different ERRs below and above the given dose and taking radiation effect modifiers as common to the two dose ranges. The increased ERR/Gy in the low-dose levels less than 0.1 Gy corresponds to the estimates of ERR higher than the expected linear line in Fig. 4.





- Abstract of LSS14 (Ozasa et al.2012)
 - The sex-averaged excess relative risk per Gy was 0.42 [95% confidence interval(CI): 0.32, 0.53] for all solid cancer at age 70 years after exposure at age 30 based on a <u>linear model</u>. Supporting LNT

Implicates threshold at 0.2Gy?

- The estimated lowest dose range with a significant ERR for all solid cancer was <u>0 to 0.20 Gy</u>, and a formal <u>dose-threshold analysis indicated no</u> <u>threshold</u>; i.e., zero dose was the best estimate of the threshold.
- (Underline by Hamaoka)

Re-Estimation

Data

- Full samples in LSS 14 on Solid cancer mortality
- Estimation
 - Model 1-7
 - AMFIT of Epicure (Preston et al.)
 - Maximizes partial likelihood
 - Model 8
 - optim of R
 - Maximize full likelihood
 - Model 1 (Linear) was also estimated with R optim to compare model fit.

Model Selection

- "Information criterions" that can compare fits of non-nested models.
 - Akaike's Information Criterion
 - AIC=deviance+ 2k
 - Bayesian Information Criterion
 - BIC =deviance+ k*log(N)
 - Here,
 - k: # of free parameters
 - N: Sample size
 - Deviance ~ (Observation Prediction by a model) → Smaller is the better
 - **k** indicates "complexity of model" \rightarrow Simpler model is the better.
 - Smaller AIC(BIC) is better model.
 - AIC and BIC
 - LSS14 data consist of N= 53782 records, thus log(N)~10.9 is larger than 2. BIC penalize more on model complexity.
 - BIC prefers simpler model than AIC.

Comparison of Estimated Models (Hamaoka 2015b, e)

				_	Estimates			Note	Information	Criterion
Mo	del		Threshold/ boundary	L1	Q1	L1 or L2	Q or Q2		AIC	BIC
1	L			L1=L2		0.423***			18307.0	18317.9
2	LQ			L1=L2		0.361***	0.038	Multi-colinear	18308.2	18321.8
3	Q			L1=L2			0.218***		18330.7	18341.6
		0+L2	1	0 (Fixed)		0.423***			18307.0	18317.9
		0+L2	5	0		0.423***			18306.8	18317.7
4	Manual	0+L2	10	0		0.422***			18306.9	18317.9
7	Threshold	0+L2	20	0		0.420***			18307.2	18318.1
		0+L2	50	0		0.416***			18308.2	18319.2
		0+L2	100	0		0.412***			18309.4	18320.3
5	Category of	dummy							18318.1	18380.9
		L1+L2	1	20.430		0.426***			18308.9	18322.5
		L1+L2	5	-22.160**		0.420***		Not Converged	18305.2	18318.9
6	Linear	L1+L2	10	-2.146		0.420***			18308.8	18322.4
	Spine	L1+L2	20	1.209		0.427***			18308.8	18322.5
		L1+L2	50	0.884		0.427***			18308.5	18322.2
		L1+L2	100	0.645		0.426***			18308.7	18322.3
		L1+L2		0.398***		0.433***			18308.8	18322.4
7	Kink at	L1Q1+L2Q 2		0.626	-0.089	0.211**	0.181**	Multi-colinear	18306.6	18325.7
	209	L1Q+L2		0.213**	0.181**	0.385***		Multi-colinear	18304.8	18321.2
		Q1+Q2			0.135***		0.330***		18309.2	18322.8
8	Threshold		-23.15 (z=-0.087)			0.417***		R-optim (Full	33286.9	33781.6
1	L					0.414***		likelihood)	33285.0	33759.8
Jote	a) Signifi	cance Lev	/el ***·1%	***5% **10	% Red	letters ind	licate sm	allest AIC a	and BIC	23

Aggregation/Tabulation of Individual Level Data

- Individual level data is tabulated by dose, sex, city, age at exposure, and attained age group.
 - Dose category: 22 intervals
 - (0.005, 0.02, 0.04, 0.06, 0.08, 0.1, 0.125, 0.15, 0.175, 0.2, 0.25, 0.3, 0.5, 0.75, 1.0, 1.25, 1.5, 1.75, 2.0, 2.5, 3 +)
- Two limitations
 - Arbitrary categorization (the number of intervals and upper and lower bound)
 - For LSS data, among 86,611 subjects, 38,509 are classified to the lowest dose category.
 - Aggregation of individual-level data cause loss of information

Table Aggre	egation Cause Loss	of Information
	Data	Variance
Raw data	1,2,3,4,5,6,7,8,9,10	Var(x)=9.17
Categorized data	1~5 x 5 samples 6~10 x 5 samples	Var(x)=6.94
	24	

Small variance leads to loss of statistical power

- Significance of parameters of Poisson regression are tested with t-value (Cameron and Trivedi 1998, Ch.3).
- Smaller variance leads to a smaller t-value, which tends to fail to reject the null hypothesis H0: β=0.

$$t = \hat{\beta} / s.e(\hat{\beta}) = \hat{\beta} \sqrt{\exp(d'\hat{\beta}) Var(d)}$$

Restricting dose range and sample reduces sample size and range of dose, both of them lead to smaller t-value that is the loss of statistical power.

Effect of Aggregation

In LSS 14, dose is categorized into 22 intervals.

- (~0.005, ~0.02, ~0.04, ~0.06, ~0.08, ~0.1, ~0.125, ~0.15, ~0.175, ~0.2, ~0.25, ~0.3, ~0.5, ~0.75, ~1.0, ~1.25, ~1.5, ~1.75, ~2.0, ~2.5, ~3.0, 3.0Gy~)
- # of record= 53782
- Aggregate them into 12 and 6 intervals.
 - 12 intervals (~0.02, ~0.06, ~0.1, ~0.15, ~0.2, ~0.3, ~0.75, ~1.25, ~1.75, ~2.5, 2.5Gy~)
 - # of record= 33973
 - 6 intervals (~0.06, ~0.15, ~0.3, ~1.25, ~2.5 , 2.5Gy~)
 - # of record= 22257
- For these data the following models are estimated.
 - Linear model β1d
 - Statistically estimated-Threshold model

0 (d<τ) β₂ (d−τ) (d≥τ)

- Estimation
 - Maximize log-likelihood with optim library of R

Effect of Aggregation

a) Linear Model											
	22	2 Catego	ories	11	1 Catego	ories	6 Categories				
	Estimate	s.e.	t-value	Estimate	s.e.	t-value	Estimate	s.e.	t-value		
Dose : Slope (/Gy)	0.413	0.051	8.07 ***	0.408	0.052	7.84 ***	0.391	0.053	7.34 ***		
Sex (male=-1, female=1)	0.340	0.088	3.88 ***	0.331	0.089	3.72 ***	0.340	0.092	3.70 ***		
Age at exposure (30 yrs old)	-0.334	0.084	-4.00 ***	-0.347	0.086	-4.04 ***	-0.364	0.092	-3.97 ***		
Attained age (70 yrs. old)	-0.949	0.382	-2.49 **	-0.878	0.390	-2.25 **	-0.823	0.407	-2.02 **		
N		53782	2		33973	3		22257	7		
AIC		33285	5		26520)		21115	5		
BIC		33760)		26973	3		21548	3		

b) Statistically estimated-threshold model

	2	2 Catego	ories	1	1 Catego	ories	6	6 Categories			
	Estimate	s.e.	t-value	Estimate	s.e.	t-value	Estimate	s.e.	t-value		
Dose : Slope (/Gy)	0.417	0.071	5.86 ***	0.408	0.074	5.55 ***	0.385	0.073	5.25 ***		
Dose : Threshold	-0.023	0.264	-0.09	0.003	0.304	0.01	0.037	0.356	0.10		
Sex (male=-1, female=1)	0.345	0.105	3.29 ***	0.330	0.108	3.07 ***	0.332	0.114	2.91 ***		
Age at exposure (30 yrs old)	-0.338	0.096	-3.53 ***	-0.346	0.100	-3.46 ***	-0.358	0.107	-3.34 ***		
Attained age (70 yrs. old)	-0.985	0.562	-1.75 *	-0.874	0.577	-1.52	-0.774	0.619	-1.25		
Ν		53782	2		33973	3		22257			
AIC		33287	7		26522	2		21117			
BIC		33782	2		26994	1		21568			

- Standard error of estimates increases and t-value decreases with aggregation as we expected.
- For Linear-threshold model, threshold shifts upward as aggregation proceeds.
- Based on this result, if individual level model was applied, lower threshold will be obtained.
- For each aggregation level, fit of Linear model is better than Linearthreshold model.
- Based on these results, liner (no threshold) model is a empirically supported model for LSS14 data.
- To detect effect of low dose, we must avoid aggregation.

- Although RERF does not provide individual data for external researchers, U.S. Department of Energy publishes individual level data of nuclear workers.
- US Nuclear worker individual-level data at 3 sites analyzed by Gilbert et al. (1993) is re-analyzed.
 - Hanford: Nuclear
 - Oak Ridge National Laboratory
 - Rocky Flats: Weapons Plant

Descriptive Statistics of Population

			Total Popu	ulation	Popu	lation for Ana	alysis*
		Hanford	Dak Ridge	Rocky Flats	Hanford	Oak Ridge	Rocky Flats
Total		44,156	8,318	7,616	33,973	6,743	6,788
Sex	Male	31,488	8,318	7,616	25,705	6,743	6,788
	Female	12,668	0	0	8,268	3 () 0
Follow-up	period Start	1944	1943	1952	1944	1944	1952
•	End	1989	1984	1987	1989) 1984	1987
Cumulativ	e doseMean	23.5	17.3	32.2	25.4	21.1	35.6
(mSv)	Median	3.0	1.4	7.4	3.7	3.5	5 9.7
	Max	1477.0	1144.0	726.0	1477.0) 1144.0	726.0
Cause of o	death						
ALL		9771	1433	794	7012	2 1208	3 719
Cancer		2390	352	214	1732	2 316	6 194
	Solid cancer	2133	302	186	1540) 271	171
	Leukemia	87	28	10	62	2 26	6 10
	Other cancer	170	22	18	130) 19) 13
Non-cance	er	6145	891	479	4446	5 74 1	437
External		911	172	100	618	3 137	<mark>′</mark> 87
Unknown		325	18	1	216	6 14	k 1

*)Following Gilbert et al.(1993), we limited analysis to workers of at least 6 months who were monitored for external radiation. We also excluded seriously exposed three workers.

• Our population is larger than Gilbert et al. (1993) because of additional follow-up years.

Individual Level Model (Amamiya 1985)

The Binomial Logit model for the specific mortality

 $P(Death by the specific cause) = \frac{1}{1 + exp(-\beta x_i)}$

The Multinomial Logit model to estimate mortality due to one of several causes of death.

$$P(Death by the cause i among m causes) = \frac{exp(\beta x_i)}{\sum_{j=1}^{m} exp(\beta x_j)}$$

Hazard model for the length of time before death due to the specific cause.

P(*Death by the specific cause at* t|*Survived until* t) = $h_0(t)exp(\beta x_i)$

Results of Estimation (Hamaoka 2015c, d)

- Gilbert et al. (1993) analyzed the tabulated data and failed to detect a significant relationship between cumulative doses and mortality.
- With the individual level data modeling, positive and significant coefficients of dose are obtained.

	Gilber	t et al(1993)		Re-Analysis	
	Trend statistics	ERR	Binomial Logit	Multinomial Logit	Hazard(@)
ALL	-0.25		2.55**		
Cancer	-0.04	-0.0 (<0, 0.8)	2.22**		
(excluding leukemia)		0.0 (<0, 0.8)	2.37**		
Solid cancer			1.88*	1.70*	0.091 *
Leukemia		-1.0 (<0, 2.2)	-0.38	-0.40	
Other cancer			2.02*	2.22**	
Non-cancer			1.78*	2.50**	
	-0.08				
External			-0.14	-0.29	
	-1.85*				
Unknown	-1.46		2.48**	2.50**	

@:For hazard model log of dose: (log(1+dose)) was employed for the analysis.

Results

- Through Logit models and hazard model, statistically significant effect of radiation dose on cancer mortality was detected.
- For the same data, the Mantel–Haenzel score test and Poisson regression failed to detect this relationship (Gilbert et al. 1993).
- To detect effect of low dose, individual level modeling is effective.

Radiation and Thyroid Nodule Fukushima Health Management Survey

Flow Chart of Thyroid Ultrasound Examination (Preliminary Baseline Screening)



A

- (A1) No nodules / cysts
- (A2) Nodules <5.0 mm or cysts <20.0 mm</p>

B

- Those with B test result are advised to take the Confirmatory Examination.
- (B) Nodules >5.1 mm or cysts >20.1 mm
- Some A2 test results may be re-classified as B results when clinically indicated.

C

- C test result are advised to take the Confirmatory Examination.
- (C) Immediate need for confirmatory examination.

Subject Municipalities of Fukushima Thyroid Screening



Results of The First Round Fukushima Thyroid Examination (As of Feb. 2015) 1) Thyroid Screening

				A1	A2	В	С	Solid I	Nodule	Су	st
	Target Popula- tion (n)	Partici- pants	Mean Age at Exposure (y)	No Specific Finding	Nodule ≤5.0 mm or/and Cyst ≤20.0 mm	Nodule ≥5.1 mm or/and Cyst ≥20.1 mm	Needed Further Examinati on	≤5 mm	≥5.1 mm	≤20 mm	≥20.1 mm
0011	47 700	41,810	0.4	26,373	15,216	221	0	232	219	15,140	1
2011	47,768	87.53%	9.4	63.10%	36.40%	0.53%	0.00%	0.55%	0.52%	36.21%	0.00%
2012	161 125	139,339	0.0	76,183	62,146	987	1	730	973	62,259	9
2012	101,135	86.47%	9.0	54.70%	44.60%	0.71%	0.00%	0.52%	0.70%	44.68%	0.01%
2012	150 701	117,428	9.6	50,460	64,415	1,042	0	718	1,040	64,704	2
2013	100,704	73.95%	0.0	43.00%	54.90%	0.89%	0.00%	0.61%	0.89%	55.10%	0.00%
Total 367,687	267 687 298,577 8.0	153,016	141,777	2,250	1	1,680	2,232	142,103	12		
	81.20%	8.9	51.20%	47.50%	0.75%	0.00%	0.56%	0.75%	47.59%	0.00%	

2) Confirmatory Examination

3) Total

			N 4	Confirm _	Reclass	sified to						Malig-	Solid N	lodules
	Target Partici- pants (n)	Particip ants for Exa- mination	Mean Age at Ex- posure (y)	ed Results of Examin ation	A1	A2	Con- firmed Results	A1	A2	Follow- up Advised	Cyto- logy	nancy (Including Suspected)	≤5 mm	≥5.1 mm
2011	221	199	14 5	197	12	44	41,786	26,385	15,260	141	91	14	276	127
2011	221	90.00%	14.0	99.00%	6.10%	22.30%	99.90%	63.10%	36.50%	0.34%	0.22%	0.03%	0.66%	0.30%
2012	000	919	15.0	899	54	246	139,228	76,237	62,392	599	262	56	976	543
2012	900	93.00%	15.0	97.80%	6.00%	27.40%	99.90%	54.80%	44.80%	0.43%	0.19%	0.04%	0.70%	0.39%
2012	1 0 4 2	949	14.0	914	51	274	115,789	50,511	64,689	589	170	39	992	550
2013	1,042	91.10%	14.9	96.30%	5.60%	30.00%	98.60%	43.60%	55.90%	0.51%	0.15%	0.03%	0.86%	0.48%
Total	2 251	2,067	1/ 0	2,010	117	564	296,803	153,133	142,341	1,329	523	109	2,244	1,220
	2,231	91.80%	14.0	97.20%	5.80%	28.10%	99.40%	51.60%	48.00%	0.45%	0.18%	0.04%	0.76%	0.41%

36

Interim report

Table 9. Proportion of B or C test results, and suspi	cious o	or ma	lignant (Interim 1	eport)	As of 31 March 2015		
			13 municipalities	Nakadori ¹⁵	Hamadori ¹⁶	Aizu ¹⁷	Total
Participants			47,768	199,451	70,539	49,927	367,685
Number of participants of Primary Examination	A ¹⁰		41,810	169,116	55,516	32,791	299,233
Mean age (SD) Total			10.4 (5.3)	10.7 (5.1)	11.2 (5.0)	11.1 (4.5)	-
Mean age (SD) Female			10.4 (5.3)	10.8 (5.2)	11.3 (5.1)	11.3 (4.6)	-
Mean age (SD) Male			10.3 (5.2)	10.6 (5.1)	11.0 (4.9)	10.9 (4.5)	-
Female (%)		%	49.6	49.3	49.9	49.7	49.5
B or C test results	В		221	1,230	505	323	2,279
Proportion of B or C test results	(B/A)	%	0.53	0.73	0.91	0.99	0.76
Number of participants of Confirmatory Examination	C ¹¹		197	1,106	448	283	2,034
Proportion of participants	(C/B)	%	89.1	89.9	<mark>88.</mark> 7	87.6	89.2
Participants of FNAC	D 12		94	296	97	48	535
Proportion of participants of Confirmatory Examination	(D/C)	%	47.7	26.8	21.7	17.0	26.3
Proportion of participants of Primary Examination	(D/A)	%	0.22	0.18	0 .17	0.15	0.18
Number of suspicious or malignant	E ¹³		14	63	23	11	111
Proportion	(E/D)	%	14.9	21.3	23.7	22.9	20.7
Proportion per 100,000	(E/A)		33.5	37.3	41.4	33.5	37.1
		%	(0.033)	(0.037)	(0.041)	(0.034)	(0.037)

37

Limitations of This "Analysis"

- Does not adjust age at exposure and attained age (age at examination).
- No statistical test.
- 59 municipalities are aggregated into four regions without rationale.
- Focusing only on thyroid cancer

Studies on Radiation and Thyroid Nodules (Hamaoka 2015a,f)

Research		Subjects	Exposure			Diagnose				Percentages of Thyroid Anomalies [Total (Male/Fenale)] (%) Risk Parameter (P-value): Under line indicates significant coefficient				
Re	Search	Gubjeeta	Year	Dose	Age	Year	N	Method	Age	Thyroid Nodule	Solid Nodule	Cancer	Cyst	
A- bomb	Nagataki et al. (1994)	General Public	1945	0.488 Sv	18.7	1984-8 7	2,857	US	59.2	6.8 (4.0/9.8)	3.2 (1.5/4.7) EOR=?(p<0.01)	0.8 (0.3/1.1) EOR=?(p=0.09)	4.1 (2.5/5.0)	
	Imaizumi et al. (2006)	General Public	1945	0.490Sv (Median= 0.087Sv)	15	2000 -2003	4,091	US	70	20.7 (12.3/24.8)	14.4 (8.0/17.6) <u>EOR=2.01/Sv</u> <u>(p<0.001)</u>	2.1 (0.8/2.8) <u>EOR=1.95/Sv</u> <u>(p<0.001)</u>	7.9 (4.7/9.5) <u>EOR=0.89/Sv</u> (p<0.001)	
	Imaizumi et al. (2015)	General Public	1945	0.182Gy (Median= 0.018Sv)	4.2	2007 -2011	2,668	US	68.2	17.6 (12.6/21.8) <u>EOR=1.65/Gy</u> <u>(p<0.001)</u>	16.0 (11.2/20.0) <u>EOR=1.72/Gy</u> <u>(p<0.001)</u>	1.8 (0.7/2.6) <u>EOR=4.4/Gy</u> <u>(p<0.001)</u>	1.8 (1.5/2.1) EOR=1.11/Gy (p=0.01)	
	Panasyuk et al. (1997)	Children (<18 yrs old)	1986-	-		1991 -1996	120,605	US		4.85		0.52	-	
Cherno byl	Inskip et al. (1997)	Worker	Vorker 1986 -91			1995	1,984	Palpa tion		7.0 (7.0/-)				
				10.8cGy	32			US	40.0	10.1 (10.1/-) ERR=-0.01/cGy (p>0.1)	3.93 (3.93/-)	0.25 (0.25/-)	0.55 (0.55/-)	
Semi- palatin sk	Land et al. (2008)	General Public	1949– 62	Ext. 0.04 Gy Int. 0.31 Gy	14	1998	2,994	US	56	30.6 (18.0/39.0) Ext. Dose EOR=2.26/Gy (p<0.05) Int. Dose EOR=0.60/Gy (p<0.05)	19.8 (11.3/25.5)	2.0 (0.6/2.9)	0.9 (0.8/1.1)	
Medica I	Schneider et al. (1993)	Patient	1939- 62	58.6cGy (Min=45.8, max=71.5)	~16	1974 -1990	2,634	Palpa tion	~44	-	39.6 (34.4/47.2) <u>ERR=0.091/cGy</u> <u>(p<0.05)</u>	11.7 (10.3/13.8) <u>ERR=0.03/cGy</u> <u>(p<0.05)</u>		
Fukush	Fukushima Pref.(2015)	Children (<18 yrs old)	2011-	Range= 11.5-58.0 mSv (*)	8.9	2011-2 014/12	298,577	US	10.7	-	1.17 (0.76: <5mm, 0.41: >5.1mm)	0.04	47.5	
ima	Sobue(20 14)	Worker	2011	122mSv		2014	627 vs 1,437 Controls	US	43 vs 41	-	14.7 vs 12.0 <u>(p=0.07)</u>	0	40.4vs29.6 (p<0.001)	
Aomori, Yamana shi, and Nagasa ki	Hayashida et al. (2013)	Children (3~18yrs old, from 3 schools.)	-	-	-	2012	4,365	US	12.0	-	1.65 (0.64: <5mm, 1.01: >5mm)	0	56.9 (52.3: <5mm, 4.58: >5mm)	

Follow-up Studies on Thyroid Nodules (Hamaoka 2015a,f)

Research		Subjects		Exposure			Diagno	ose		Percentages of Thyroid Cancer (%) Risk Paremeter (P- value)
			Year Dose		Age	Year	Ν	Method	Age	Cancer
A-bomb	Imaizumi et al. (2005)	General Public	1945	0.488 Sv	18.7	1984-87	2,637 (82 solid nodules, 121 cysts, and 2434 nodule- free controls)	US	59	Control Group 0.3 % Solid nodule Group 7.3% <u>HR=23.6(p<0.05)</u> Cyst Group 0.8 % HR=23.6(p>0.05)
Cherno- byl	Hayashi da et al. (2012)	Children	1986-	-	6.0	2009-20 10	160 cases/ 160 controls	US	29.0	Malignancy 1.9% vs <u>0% (p=0.08)</u> Suspicious of malignancy (FNAB) 7.5% vs 0% (p<0.001) -
					4	0	S	ource) i	bid.	

Thyroid Dose Estimates for 10 Years Old (UNSCEAR 2013)



Thyroid Dose and Nodules (≤5mm) for Each Municipality



Relationships among Age at Examination, Age at Exposure &, Nodules (≤ 5 , ≥ 5.1 mm) and Malignancy



Analysis

- Samples
 - Cities and villages that completed screening between 2011 and 2013 (N=59)
- Poisson regression
 - # of confirmed test results were considered as the offset
- Dependent variables
 - # of nodules with diameter ≤5 mm, ≥5.1 mm, and thyroid cancer (including suspicious cases)
- Explanatory variables (Expected sign)
 - Thyroid Dose (+)
 - Mean age at exposure (-)
 - Mean age at screening (+)

Table 4. Results of Poisson Regression

			(a) Nodule	≤5 mm		
	Coeff.	s.e.	t-value	p-value	95% CI	
Intercept	-1.55	0.83	-1.88	0.06*	(-3.17,	0.07)
Age at screening	0.04	0.05	0.74	0.46	(-0.06,	0.13)
Age at exposure	-0.47	0.07	-7.13	0.00***	(-0.60,	-0.34)
Thyroid dose (Sv)	18.76	3.79	4.95	0.00***	(11.33,	26.18)
		(2)) Nodule ≥5.2	1 mm		
	Coeff.	s.e.	t-value	p-value	95% CI	
Intercept	-5.44	1.12	-4.85	0.00***	(-7.64,	-3.24)
Age at screening	0.23	0.07	3.36	0.00***	(0.09,	0.36)
Age at exposure	-0.31	0.09	-3.53	0.00***	(-0.48,	-0.14)
Thyroid dose (Sv)	11.45	5.3	2.16	0.03**	(1.06,	<u>21.85)</u>
		()	c) Nodule (To	otal)		
	Coeff.	s.e.	t-value	p-value	95% CI	
Intercept	-2.27	0.67	-3.41	0.00***	(-3.57,	-0.96)
Age at screening	0.1	0.04	2.59	0.01***	(0.03,	0.18)
Age at exposure	-0.41	0.05	-7.84	0.00***	(-0.52,	-0.31)
Thyroid dose (Sv)	16.26	3.09	5.27	0.00***	(10.21,	22.31 <u>)</u>
	(d)	Maligna	ancy (includii	ng suspicious)		
	Coeff.	s.e.	t-value	p-value	95% CI	
Intercept	-8.03	3.67	-2.19	0.03**	(-15.23,	-0.84)
Age at screening	0	0.22	-0.02	0.99	(-0.44,	0.43)
Age at exposure	-0.03	0.29	-0.09	0.93	(-0.58 <i>,</i>	0.53)
Thyroid dose (Sv)	15.9	15.78	1.01	0.31	(-15.03,	46.83)
	Si	gnifica	ince levels	s: ***1%, **5%,	and *10%	4.

Summary and Discussion (1/2)

- The UNSCEAR thyroid dose had positive and significant coefficients for both smaller and larger nodules.
- Age at screening was positive, and age at exposure was negative, as we expected.
 - For the thyroid dose estimate by WHO (2013) and National Institute of Radiation Science (2012), similar results were obtained. However, for the external dose estimates by Fukushima Basic Survey, the coefficient was insignificant.
 - Reconstruction of dose is necessary.
- They were insignificant for malignancy, due to lack of statistical power to detect differences at prevalence of malignancy of 0.03% with sample size of 59 municipalities.
 - Individual level analysis should be conducted. Case-control study would be efficient.

Summary and Discussion (2/2)

- Although this was an ecological study at the municipality level, our results are consistent with previous studies.
- According to follow up studies of a-bomb (Imaizumi et al 2005) and Chernobyl (Hayashida et al. 2012), nodule group has larger risk of thyroid cancer. Our results might indicate an early warning for future incidence of thyroid cancer.
 - An immediate measure is urgently needed.
- Additionally, insufficient information disclosure caused distrust of the Japanese central and local governments. Proper measurement, timely provision of information, and information disclosure are necessary.

Concluding Remarks

- For Experts
 - Radiation epidemiologists, doctors, and other "experts" seems to lack in knowledge on statistics. As experts, they should learn statistics.
- Data analysis
 - Standard analysis procedure that tabulates individual level data has serious limitations. Re-analysis with individual level data and modeling is necessary to detect lower dose effect.
 - Opening anonymized individual data will be effective to promote research in the field.
- Policy making
 - Policy making on radiation protection needs long time: UNSCEAR reviews and publishes reports every some ten years, ICRP publishes recommendations based on the UNSCEAR reports, and each country government makes policy based on their recommendations (Crick 2011). The base of present recommendation and policy is the UNSCEAR 2006 report that stands on findings of LSS13 (Preston et al.). Reformation of decision making system that can update policy promptly is necessary.
 - Experts and policy makers should understand that UNSCEAR reports, ICRP recommendations, and government policies stand on "old" knowledge. They should review the latest findings and respond promptly with "precautionary principle."

- This report makes use of data obtained from the Radiation Effects Research Foundation (RERF), Hiroshima and Nagasaki, Japan. RERF is a private, non-profit foundation funded by the Japanese Ministry of Health, Labour and Welfare (MHLW) and the U.S. Department of Energy (DOE), the latter in part through DOE Award DE-HS0000031 to the National Academy of Sciences. The conclusions in this report are those of the authors and do not necessarily reflect the scientific judgment of RERF or its funding agencies.
- Access to nuclear worker data was granted by the US DOE CEDR project. The protocol and results of this study were not reviewed by the DOE. The results and conclusions do not necessarily reflect those of the US Government or DOE.

Reference

- Amemiya, Takeshi (1985), Advanced Econometrics: Harvard University Press.
- Cameron and Trivedi (1998), Regression Analysis of Count Data: Cambridge University Press.
- Cardis, Elisabeth, Howe, Geoffrey, Ron, Elaine, Bebeshko, Vladimir, Bogdanova, Tetyana, Bouville, Andre, . . . Zvonova, Irina. (2006). Cancer consequences of the Chernobyl accident: 20 years on. Journal of Radiological Protection, 26(2), 127-140. doi: 10.1088/0952-4746/26/2/001
- Gilbert, Ethel S., Donna L. Cragle, and Laurie D. Wiggs (1993), "Updated Analyses of Combined Mortality Data for Workers at the Hanford Site, Oak Ridge National Laboratory, and Rocky Flats Weapons Plant," Radiation Research, 136 (3), 408-21.
- Hamaoka, Yutaka (2013)"A Possible Warning from Fukushima: A Preliminary Analysis of Radiation Dose and Occurrence of Thyroid Nodules Using City- and Village-level Data," MELODI 2013Workshop, Brussels, Belgium, Oct. 8, 2013, (abstract accepted for Oral Presentation)
- Hamaoka , Yutaka (2015a), "An Analysis of Fukushima Thyroid Examination," Kagaku, June. (in Japanese)
- Hamaoka , Yutaka (2015b), "Re-Analysis of LSS Data,". Kagaku, Sep. (in Japanese)
- Hamaoka, Yutaka (2015c), "Research on Prolonged Radiation Exposure and Health Effect,". Kagaku, Oct. (in Japanese)
- Hamaoka, Yutaka (2015d)"It is time to say goodbye to Poisson Regression III: Application of Individual Level Model to Nuclear Worker Data," 2015 International Conference on Radiation Research, Kyoto: Japan, May 19-22, 2015, (abstract accepted for poster)
- Hamaoka, Yutaka (2015e)"Re-Analysis of A-bomb Survivor Data Supports LNT Model: How to Select Best Model," 2015 International Conference on Radiation Research, Kyoto: Japan, May 19-22, 2015, (abstract accepted for oral presentation)
- Hamaoka, Yutaka (2015f)"A Possible Warning from Fukushima III:An Analysis of Radiation Dose and Prevalence of Thyroid Nodules Using Municipality-level Data," 2015 International Conference on Radiation Research, Kyoto: Japan, May 19-22, 2015,
- Hayashida, N., et al., Prognosis of thyroid nodules in individuals living in the Zhitomir region of Ukraine. PLoS One, 2012. 7(11): p. e50648.
- Imaizumi, M., T. Usa, T. Tominaga, M. Akahoshi, K. Ashizawa, S. Ichimaru, E. Nakashima, R. Ishii, E. Ejima, A. Hida, M. Soda, R. Maeda, S. Nagataki, and K. Eguchi (2005), "Long-term prognosis of thyroid nodule cases compared with nodule-free controls in atomic bomb survivors," J Clin Endocrinol Metab, 90 (9), 5009-14.

Reference

- Imaizumi, M., T. Usa, T. Tominaga, K. Neriishi, M. Akahoshi, E. Nakashima, K. Ashizawa, A. Hida, M. Soda, S. Fujiwara, M. Yamada, E. Ejima, N. Yokoyama, M. Okubo, K. Sugino, G. Suzuki, R. Maeda, S. Nagataki, and K. Eguchi (2006), "Radiation dose-response relationships for thyroid nodules and autoimmune thyroid diseases in Hiroshima and Nagasaki atomic bomb survivors 55-58 years after radiation exposure," JAMA, 295 (9), 1011-22.
- Land, C. E., Z. Zhumadilov, B. I. Gusev, M. H. Hartshorne, P. W. Wiest, P. W. Woodward, L. A. Crooks, N. K. Luckyanov, C. M. Fillmore, Z. Carr, G. Abisheva, H. L. Beck, A. Bouville, J. Langer, R. Weinstock, K. I. Gordeev, S. Shinkarev, and S. L. Simon (2008), "Ultrasound-Detected Thyroid Nodule Prevalence and Radiation Dose from Fallout," Radiation Research, 169 (4), 373-83.
- Nagataki, S., Y. Shibata, S. Inoue, N. Yokoyama, M. Izumi, and K. Shimaoka (1994), "Thyroid diseases among atomic bomb survivors in Nagasaki," JAMA, 272 (5), 364-70.
- Ozasa, Kotaro, Yukiko Shimizu, Akihiko Suyama, Fumiyoshi Kasagi, Midori Soda, Eric J. Grant, Ritsu Sakata, Hiromi Sugiyama, and Kazunori Kodama (2012), "Studies of the Mortality of Atomic Bomb Survivors, Report 14, 1950–2003: An Overview of Cancer and Noncancer Diseases," Radiation Research, 177 (3), 229-43.
- Preston, DL, Shimizu, Y, Pierce, DA, Suyama, A, & Mabuchi, K. (2003). Studies of mortality of atomic bomb survivors. Report 13. Solid cancer and noncancer disease mortality: 1950-1997. Radiation Research, 160(4), 381-407.
- Sugiyama, H., Misumi, M., Kishikawa, M., Iseki, M., Yonehara, S., Hayashi, T., Soda, M., Tokuoka, S., Shimizu, Y., Sakata, R., Grant, E. J., Kasagi, F., Mabuchi, K., Suyama, A., & Ozasa, K. 2014. Skin Cancer Incidence among Atomic Bomb Survivors from 1958 to 1996. Radiat Res, 181(5): 531-539.
- UNSCEAR. 2014. UNSCEAR 2013 REPORT Volume I: Report to the General Assembly, Scientific Annex A: Levels and effects of radiation exposure to the nuclear accident after the 2011 great east-Japan earthquake and tsunami. (http://www.unscear.org/docs/reports/2013/13-85418_Report_2013_Annex_A.pdf).
- WHO (2013), "Health risk assessment from the nuclear accident after the 2011 Great East Japan earthquake and tsunami, based on a preliminary dose estimation," http://www.who.int/ionizing_radiation/pub_meet/ fukushima_risk_assessment_2013/en/index.html.